ENIGMA-TRS 1 is an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients; enrollment to start imminently; 12-week study results expected in Q4 2026 ...
Newron today announced its financial results and operational highlights for the business year ended Dec. 31, 2025, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results